Bank of New York Mellon Corp Purchases 20,688 Shares of Bruker Corporation (BRKR)

Bank of New York Mellon Corp boosted its position in Bruker Corporation (NASDAQ:BRKR) by 3.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 704,066 shares of the medical research company’s stock after buying an additional 20,688 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.44% of Bruker Corporation worth $20,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. Alps Advisors Inc. increased its position in Bruker Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,154 shares of the medical research company’s stock worth $581,000 after buying an additional 52 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Bruker Corporation in the second quarter worth $111,000. First Trust Advisors LP purchased a new stake in Bruker Corporation in the second quarter worth $809,000. Boston Partners increased its position in Bruker Corporation by 3.6% in the second quarter. Boston Partners now owns 2,773,019 shares of the medical research company’s stock worth $79,973,000 after buying an additional 96,791 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in Bruker Corporation by 5.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 555,025 shares of the medical research company’s stock worth $16,007,000 after buying an additional 30,500 shares during the last quarter. 65.42% of the stock is owned by institutional investors and hedge funds.

In other Bruker Corporation news, CEO Frank H. Laukien purchased 2,335 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average price of $27.39 per share, with a total value of $63,955.65. Following the acquisition, the chief executive officer now owns 37,791,386 shares in the company, valued at $1,035,106,062.54. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Mark Munch sold 21,061 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is currently owned by company insiders.

BRKR has been the subject of a number of analyst reports. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, July 6th. Wells Fargo & Company lowered Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Cowen and Company reaffirmed a “hold” rating and issued a $29.00 price target on shares of Bruker Corporation in a report on Friday, July 14th. Barclays PLC reaffirmed an “equal weight” rating and issued a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Finally, BidaskClub lowered Bruker Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $27.00.

Shares of Bruker Corporation (NASDAQ BRKR) opened at 29.85 on Friday. The firm’s 50-day moving average price is $28.49 and its 200-day moving average price is $26.46. The stock has a market cap of $4.74 billion, a P/E ratio of 29.76 and a beta of 1.10. Bruker Corporation has a 52-week low of $19.59 and a 52-week high of $30.22.

Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.20 by $0.03. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The business had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The business’s revenue was up 11.6% on a year-over-year basis. Equities analysts predict that Bruker Corporation will post $1.12 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 22nd. Investors of record on Tuesday, September 5th will be issued a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date is Thursday, August 31st. Bruker Corporation’s payout ratio is 16.00%.

WARNING: This news story was first reported by Equities Focus and is the property of of Equities Focus. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.equitiesfocus.com/2017/09/17/bank-of-new-york-mellon-corp-purchases-20688-shares-of-bruker-corporation-brkr.html.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Institutional Ownership by Quarter for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply